<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04866667</url>
  </required_header>
  <id_info>
    <org_study_id>zjPPHNFM001</org_study_id>
    <nct_id>NCT04866667</nct_id>
  </id_info>
  <brief_title>Observational Study of ASCVD Risks of Type 2 Diabetes in East China</brief_title>
  <official_title>Screening and Intervention of Arteriosclerotic Cardiovascular Disease in Type 2 Diabetes in Zhejiang Province</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang Provence Preventive Medicine Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo Medical Center Lihuili Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Cixi Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Putuo People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second People's Hospital of Yuhuan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wenling People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ShuGuang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Jiaxing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanxun People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital Affiliated to Huzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lishui Hospital of TCM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hangzhou hospital of Chinese Traditional Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Greentown Cardiovascular Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Red Cross Hospital of Hangzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second School of Medicine，WMU</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Xiaoshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Xiaoshan hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yiwu Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quzhou Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinhua Hospital of TCM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaoxing Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaoxinig Second Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huamei hospital, University of Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Provincial People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to screen patients with type 2 diabetes with high risk of&#xD;
      cardiovascular disease, and intervene with or without Glucagon like peptide-1 receptor&#xD;
      agonists.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>New-onset cardiovascular events</measure>
    <time_frame>maximum 2 years</time_frame>
    <description>Composite of angina pectoris, stroke, myocardial infarction, atherosclerotic plaque，unplanned rehospitalization, stent thrombosis, incidence of cardiac death in the duration of follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood glucose control</measure>
    <time_frame>maximum 2 years</time_frame>
    <description>Change of fasting and postprandial blood glucose in the duration of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid levels</measure>
    <time_frame>maximum 2 years</time_frame>
    <description>Change of lipid levels（Total cholesterol, Total triglycerides, low density lipoprotein，high density lipoprotein） in the duration of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure level</measure>
    <time_frame>maximum 2 years</time_frame>
    <description>Change of blood pressure（mmHg） in the duration of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>maximum 2 years</time_frame>
    <description>Change of body weight(kg) in the duration of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Distribution Indicators</measure>
    <time_frame>maximum 2 years</time_frame>
    <description>Change of abdomen circumference（cm） in the duration of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Distribution Indicators</measure>
    <time_frame>maximum 2 years</time_frame>
    <description>Change of waist circumference（cm） in the duration of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular complications</measure>
    <time_frame>maximum 2 years</time_frame>
    <description>Microvascular complications（such as Diabetic retinopathy，Diabetic nephropathy） in the duration of follow-up</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Arteriosclerotic Cardiovascular Disease</condition>
  <condition>Liraglutide</condition>
  <arm_group>
    <arm_group_label>antidiabetic drugs including GLP-1 RAs</arm_group_label>
    <description>Apply Type 2 Diabetes mellitus patients with high risk of ASCVD with antidiabetic drugs including GLP-1 RAs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antidiabetic drugs not including GLP-1 RAs</arm_group_label>
    <description>Apply Type 2 Diabetes mellitus patients with high risk of ASCVD with antidiabetic drugs not including GLP-1 RAs，such as metformin，insulin</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 diabetes patients over 18 years old with high risks of atherosclerotic&#xD;
        cardiovascular disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  HbA1c ≥7.0%&#xD;
&#xD;
          -  Prior CVD cohort: age ≥50 and ≥1 of the following criteria.&#xD;
&#xD;
               -  Prior MI&#xD;
&#xD;
               -  Prior stroke or TIA&#xD;
&#xD;
               -  Prior coronary, carotid or peripheral arterial revascularization&#xD;
&#xD;
               -  N50% stenosis of coronary, carotid, or lower extremity arteries&#xD;
&#xD;
               -  History of symptomatic CHD documented by Positive exercise stress test or any&#xD;
                  cardiac imaging or Unstable angina with ECG changes&#xD;
&#xD;
               -  Asymptomatic cardiac ischemia Documented by positive nuclear imaging test,&#xD;
                  exercise test or dobutamine stress echo&#xD;
&#xD;
               -  Chronic heart failure NYHA class II-III&#xD;
&#xD;
               -  Chronic renal failure, eGFR &lt;60 mL/min per 1.73m2 MDRD eGFR &lt;60 mL/min per&#xD;
                  Cockcroft-Gault formula&#xD;
&#xD;
          -  No Prior CVD group: Age ≥60 y and ≥1 of the following criteria.&#xD;
&#xD;
               -  Microalbuminuria or proteinuria&#xD;
&#xD;
               -  Hypertension and left ventricular hypertrophy by ECG or imaging&#xD;
&#xD;
               -  Left ventricular systolic or diastolic dysfunction by imaging&#xD;
&#xD;
               -  Ankle-brachial index b0.9&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  other type diabetes&#xD;
&#xD;
          -  Calcitonin ≥50 ng/L&#xD;
&#xD;
          -  Use of a GLP-1 receptor agonist (exenatide, liraglutide or other) or pramlintide or&#xD;
             any DPP-4 inhibitor within the 3 months prior to screening&#xD;
&#xD;
          -  Use of insulin other than human NPH insulin or long-acting insulin analogue or&#xD;
             premixed insulin within 3 months prior to screening. Shortterm use of other insulin&#xD;
             during this period in connection with intercurrent illness is allowed, at&#xD;
             Investigators discretion&#xD;
&#xD;
          -  Acute decompensation of glycemic control&#xD;
&#xD;
          -  An acute coronary or cerebrovascular event in the previous 14 d&#xD;
&#xD;
          -  Currently planned coronary, carotid, or peripheral artery revascularization&#xD;
&#xD;
          -  Chronic heart failure (NYHA class IV)&#xD;
&#xD;
          -  Current continuous renal replacement therapy&#xD;
&#xD;
          -  End-stage liver disease&#xD;
&#xD;
          -  History of solid organ transplant or awaiting solid organ transplant&#xD;
&#xD;
          -  Malignant neoplasm&#xD;
&#xD;
          -  Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial&#xD;
             medullary thyroid carcinoma (FMTC)&#xD;
&#xD;
          -  Personal history of non-familial medullary thyroid carcinoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaohong Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocriology, Zhejiang Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao Ye, MD</last_name>
    <phone>+86-571-85893937</phone>
    <email>semper_fi@foxmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu Lei, MD</last_name>
    <phone>+86-571-85893937</phone>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Provincial People's Hospital</investigator_affiliation>
    <investigator_full_name>Xiao Ye, MD</investigator_full_name>
    <investigator_title>Director Assistant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

